A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

NCT04523272 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

528

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cancer

Interventions

DRUG: TQB2450
DRUG: Anlotinib
DRUG: Sunitinib

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.